Fortune December 10, 2024
Beth Greenfield

Tavapadon, a drug being tested to treat early Parkinson’s disease, has shown great promise in a Phase III trial by AbbVie, the pharmaceutical company announced this week.

Parkinson’s disease, which is lifelong, progressive and has no cure, occurs when brain cells that make dopamine, a chemical that coordinates movement, stop working or die, according to the Michael J. Fox Foundation for Parkinson’s Research. This causes tremors,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma / Biotech, Trends
Overcoming the first hurdles: Navigating early phase challenges for biotechs
Healthy Returns: A huge deal to boost Novo Nordisk's manufacturing is one step closer to closing
Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
Chroma, Nvelop merge to marry genetic medicine ‘cargo’ to delivery
Rare Disease, Big Impact with Matt Wilsey

Share This Article